Suven Pharmaceuticals Renamed as Cohance Lifesciences
ECONOMY & POLICY

Suven Pharmaceuticals Renamed as Cohance Lifesciences

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences.

This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics.

The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide.

"The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world" said Cohance Executive Chairman, Vivek Sharma.

The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals” to “Cohance Lifesciences”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation.

The Company would make necessary application to the BSE and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences.”

Suven Pharmaceuticals, an integrated CDMO serving customers across the globe, has rebranded as Cohance Lifesciences. This event represents more than just a name change—it marks a bold step forward in the company’s evolution into a specialized, technology-driven global CDMO platform, purpose-built for the future of therapeutics. The Cohance name captures the organization’s commitment to Collaborate with global innovators to Enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide. The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world said Cohance Executive Chairman, Vivek Sharma. The Ministry of Corporate Affairs, Government of India (“MCA”), has approved change of name of the Company from “Suven Pharmaceuticals” to “Cohance Lifesciences”, with effect from May 7, 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation. The Company would make necessary application to the BSE and the National Stock Exchange of India Limited for effecting change of name of the Company in due course. We further inform that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name “Suven Pharmaceuticals” wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name “Cohance Lifesciences.”

Next Story
Resources

Haworth India Hosts Women’s Leadership Panel Series

Haworth India marked International Women’s Day by hosting a leadership roundtable series titled ‘Give to Gain’, bringing together senior women leaders from architecture and design firms, corporates and project management consultancies. The series has been conducted in Delhi and Mumbai, with upcoming sessions scheduled in Bengaluru and Hyderabad on 27 March 2026. Structured as moderated panel discussions followed by audience interaction, the initiative examined the business impact of women’s leadership and the role of inclusive workplaces in supporting professional growth. Manish Khan..

Next Story
Real Estate

Max Estates Secures RERA For Max One Project

Max Estates has secured RERA approval (UPRERA No.: UPRERAPRJ9759) for its Max One development around Max Towers in Sector 16B, Noida, bringing renewed progress to a project previously stalled following the insolvency of its earlier developer. Spread across around 10 acres with an estimated development potential of about 2.5 million sq ft, Max One is planned as an integrated mixed-use campus combining serviced residences, premium offices, retail spaces and a private club. The project is expected to generate total sales potential of about Rs 20 billion along with an estimated annuity rental inc..

Next Story
Real Estate

Hindware Introduces Starc Smart Wall Mount Toilet

Hindware has introduced the Starc Smart Wall-Mount Toilet under its Hindware Italian Collection, designed to combine automation, hygiene and contemporary bathroom aesthetics. The model features automatic flushing, sensor-based seat opening and closing, and remote-controlled functions. It also includes an oscillating water spray and warm air dryer for cleaning, along with a self-cleaning nozzle designed to maintain hygiene. Additional features include adjustable heated seating, customisable water temperature and pressure settings, a foot-touch flush system and an LCD control interface. The wa..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement